View Older Stories View More Recent Stories
-
Tempus AI (TEM) Files Mixed Shelf
-
Tempus AI, Inc (TEM) Tops Q2 EPS by 3c
-
Tempus AI, Inc (TEM) Reports Q2 Loss of $0.22, provides guidance
-
Tempus AI (TEM) call put ratio 1.6 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 2.1 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 1.8 calls to 1 put quarter results
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Tempus receives FDA clearance for heart condition detection software
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
TEM INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
-
Personalis extends Tempus partnership to include colorectal cancer testing
-
Tempus AI expands care pathway platform to breast cancer
-
TEM INVESTOR NOTICE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR DEADLINE: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
-
Tempus AI (TEM) Announces Proposed $400M Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
INVESTOR ALERT: Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - TEM
-
TEM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Tempus AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
Tempus AI (TEM) Announces Collaboration with Northwestern University’s Abrams Research Center on Neurogenomics to Leverage AI for Alzheimer’s Disease Research
-
ROSEN, A LEADING LAW FIRM, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
ROSEN, NATIONALLY REGARDED INVESTOR RIGHTS COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Tempus AI, Inc. Investors to Inquire About Securities Class Action Investigation - TEM
-
TD Cowen Defends Tempus AI Inc (TEM): 'Stock Reaction Looks Overdone'
-
Tempus AI (TEM) Introduces xM, An Assay to Monitor Immunotherapy Response for Patients with Advanced Cancers
-
Tempus AI (TEM) Mentioned as Short at Spruce Point
-
Tempus AI (TEM) Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment
-
Tempus AI (TEM) Enters Multi-Year Strategic Collaboration With Boehringer Ingelheim to Advance Its Cancer Pipeline
-
Morgan Stanley on Tempus AI Inc (TEM): 'Solid Start to the Year'
-
Tempus AI, Inc (TEM) Tops Q1 EPS by 2c
-
Tempus AI (TEM) Introduces Loop
-
Tempus AI (TEM) Signs Expanded Strategic Agreements with AstraZeneca and Pathos to Develop the Largest Multimodal Foundation Model in Oncology
-
BTIG Starts Tempus AI Inc (TEM) at Buy
-
Illumina (ILMN) and Tempus (TEM) partner to drive the future of precision medicine through genomic AI innovation
-
Tempus AI (TEM) to acquire Deep 6 AI
-
Stifel Reiterates Hold Rating on Tempus AI Inc (TEM)
-
Tempus AI (TEM) Files for 4.84M Share Offering by Selling Stockholders
-
JPMorgan Downgrades Tempus AI Inc (TEM) to Neutral
-
After-hours movers: Zoom, Hims & Hers Health, Tempus AI, and more
-
Tempus AI, Inc (TEM) Reports Q4 Loss of $0.18
-
Tempus AI (TEM) call put ratio 1.6 calls to 1 put into quarter results and outlook
-
Tempus AI (TEM) call put ratio 1.4 calls to 1 put into quarter results
-
Tempus AI (TEM) call put ratio 2.3 calls to 1 put into quarter results
-
Tempus AI (TEM) and Stemline Therapeutics Collaborate to Implement Tempus Next
-
Tempus AI (TEM) call put ratio 1.9 calls to 1 put into quarter results
-
Ares Management (ARES) provides Tempus with total debt package of $560 million
-
Increasing unusual put option volume: GDDY SMMT FITB AUR TXRH VTRS MNST SATS KC TEM TWLO

